Memo Therapeutics
Dr. Philippe Dro serves a Partner at Adjuvant Capital. He is trained in industrial pharmacy and finance. He has built a successful career in the European biotech and medtech sectors, serving on the boards of several startup and scaleups, initiating and executing notable strategic transactions. His experience includes CEO of GlycoVaxyn, leading it through to its acquisition by GSK. Before that, he led Endoart as CEO through a successful turnaround leading to its acquisition by Allergan.
This person is not in the org chart
This person is not in any offices
Memo Therapeutics
Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis.